Search clinical trials for: Trospium Chloride, Extended Release (XR)

Total 847 results

Alcobra Ltd.

Completed

Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects

Attention Deficit Hyperactivity Disorder

Israel
Walter Reed National Military Medical Center

Unknown

Efficacy of Extended-Release Liposomal Bupivacaine for Post-Operative Urogynecologic Surgery

Postoperative Pain

United States
University of Rochester
Endo Pharmaceuticals

Terminated

Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis

Multiple Sclerosis | Chronic Pain | Neuropathic Pain

United States
Lars Tanum
Oslo University Hospital; Haukeland University Hospital; The Hospital of Vestfold and other collaborators

Completed

Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery (NaltRec)

Opioid-use Disorder

Norway
University of Pennsylvania
Patient-Centered Outcomes Research Institute

Completed

Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone (OAPXRNTX)

Opiate Dependence

United States
University of California, San Francisco
National Institute on Drug Abuse (NIDA); Pfizer

Completed

Maintaining Nonsmoking

Nicotine Dependence

United States
Endo Pharmaceuticals

Completed

Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain

Cancer | Chronic Pain | Neuropathic Pain
Pfizer

Terminated

Actual Use and Compliance Study Of Ibuprofen 600 Mg Immediate Release/Extended Release Tablets In At-Risk OTC Consumers

Pain

United States
Pfizer

Completed

Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet

Analgesia

United States
Indivior Inc.

Completed

Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

Opioid Use Disorder

United States
UConn Health

Completed

Vaccination Efficacy With Metformin in Older Adults (VEME)

Aging | Vaccine Response Impaired | Age-Related Immunodeficiency

United States
University of Hawaii
United States Department of Defense

Completed

Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

HIV Infections | Dyslipidemia | Endothelial Dysfunction

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

Cigarette Smoking-Related Carcinoma

United States
APOGEPHA Arzneimittel GmbH

Completed

Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity

Urologic Diseases | Urinary Incontinence | Urinary Bladder, Neurogenic | Neurogenic Urinary Bladder Disorder | Bladder Disorder, Neurogenic | Urinary Bladder Disorder, Neurogenic | Neurogenic Bladder Disorder | Urinary Bladder Neurogenic Dysfunction | Overactive Detrusor Function

Romania, Austria, Germany
NYU Langone Health
National Institute on Drug Abuse (NIDA)

Withdrawn

Assessing Optimal XR-Buprenorphine Initiation Points in Jail

Opioid Use Disorder

United States
George Thanassoulis
Jewish General Hospital; Laval University; Quebec Heart Institute

Withdrawn

Early Aortic Valve Lipoprotein(a) Lowering Trial (EAVaLL)

Aortic Stenosis and Lipoprotein(a) Levels

Canada
North Texas Veterans Healthcare System
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis (ALPINE-SVG)

Aortocoronary Saphenous Vein Bypass Graft Atherosclerosis | Intermediate Saphenous Vein Graft Lesions

United States
XenoPort, Inc.

Completed

Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance

Restless Legs Syndrome | Restless Legs Syndrome (RLS)

United States
NLS Pharmaceutics

Not yet recruiting

A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 (AMAZE)

Narcolepsy Type 1 | Narcolepsy With Cataplexy
Vivani Medical, Inc
Medpace, Inc.

Not yet recruiting

Assessment of Safety, Tolerability and Drug Levels of NPM-119 in Participants With Type 2 Diabetes (LIBERATE-1)

Type 2 Diabetes
University of Miami

Terminated

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

Diabetes Mellitus, Type 2 | Kidney Failure, Chronic | Hyperlipidemia

United States
University of Arkansas
National Institute on Drug Abuse (NIDA); Baylor College of Medicine

Completed

Doxazosin for Psychostimulant Dependence

Methamphetamine or Cocaine Dependence

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of, United States, Mexico, India, Puerto Rico, Russian Federation
University Hospital Schleswig-Holstein

Completed

Safety and Pharmacokinetics of Oral Controlled-ileocolonic-release Nicotinamide (CICR-NAM)

Safety Issues | Pharmacokinetic

Germany
Prof. Huss

Terminated

Adherence to Stimulant Treatment in Attention-Deficit Hyperactivity Disorder (ADHD) Patients (ASTA) (ASTA)

ADHD

Germany
McGill University
Université de Montréal

Not yet recruiting

A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

Amyotrophic Lateral Sclerosis

Canada
Rothman Institute Orthopaedics

Completed

Local Intraoperative Analgesic Injection Versus Single Injection Interscalene Nerve Block in Patients Undergoing TSA

Osteoarthritis: Shoulder
Tris Pharma, Inc.
Premier Research Group plc

Completed

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

ADHD

United States
Daniel A. Siniawski
Merck Sharp & Dohme LLC

Terminated

Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease

Coronary Artery Disease | Dyslipidemias

Argentina
University of Minnesota

Completed

Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity

Severe Obesity

United States
Yale University
National Institute on Drug Abuse (NIDA); Baystate Medical Center

Completed

Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations (NewHope)

HIV | Opioid Dependence | AIDS | Drug Dependence

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

Healthy

United States
Indivior Inc.

Active, not recruiting

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

Moderate to Severe Opioid-use Disorder

United States, Canada
University of Colorado, Denver

Completed

Intrathecal Morphine Versus Epidural Extended Release Morphine for Pediatric Patients Undergoing Spinal Fusion

Scoliosis | Pain Management | Spinal Fusion

United States
Indivior Inc.

Completed

Open-Label Treatment Extension Study

Opioid Use Disorder | Opioid-related Disorders

United States
Boehringer Ingelheim

Completed

Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease

Parkinson Disease
Samsung Medical Center
Pfizer

Completed

Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder

Overactive Bladder

Korea, Republic of
NYU Langone Health
Alkermes, Inc.

Completed

Extended-release Naltrexone for Alcohol Dependence in Primary Care

Alcohol Dependence

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

A Sequenced Behavioral and Medication Intervention for Cocaine Dependence

Cocaine Dependence

United States
NYU Langone Health
Winthrop University Hospital

Withdrawn

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

Prader-Willi Syndrome

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence (TACT2)

Cocaine Dependence

United States
Oregon Health and Science University
National Institute on Drug Abuse (NIDA)

Completed

Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study (CHOICES)

Opioid Use Disorder | Alcohol Use Disorder

Canada, United States
Merck KGaA, Darmstadt, Germany

Completed

Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis

Multiple Sclerosis

Korea, Republic of
Maimonides Medical Center

Recruiting

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome (PWS-GXR)

Aggression | Behavioral Symptoms | Pathologic Processes | Nervous System Diseases | Obesity | Neurologic Manifestations | Neurobehavioral Manifestations | Congenital Abnormalities | Overnutrition | Nutrition Disorders | Genetic Diseases, Inborn | Intellectual Disability | Self-Injurious Behavior | Abnormalities, Multiple and other conditions

United States
Walter Reed National Military Medical Center

Completed

Local Anesthetics on Postsurgical Analgesia Following Posterior Colporrhaphy

Postoperative Pain

United States
Shire

Completed

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention-deficit/Hyperactivity Disorder

Spain, Belgium, United States, Netherlands, United Kingdom, Italy, Germany, Canada, France, Sweden
Jacobus Pharmaceutical

Terminated

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children

Crohn's Disease

United States
Rhode Island Hospital
National Institute on Drug Abuse (NIDA); Alkermes, Inc.

Completed

Pre-Release VIVITROL for Opioid Dependent Inmates

Substance-Related Disorders

United States
Chemi S.p.A.

Completed

Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea

Lymphorrhea

Italy
The University of Texas Health Science Center at...
Shire

Completed

Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

United States

Search clinical trials for: Trospium Chloride, Extended Release (XR)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations